Ivabradine added to usual care in patients with heart failure: a systematic review with meta-analysis and trial sequential analysis.

Mathias MaagaardEmil Eik NielsenNaqash Javaid SethiNing LiangSi-Hong YangChristian GluudJanus Christian Jakobsen
Published in: BMJ evidence-based medicine (2021)
High certainty evidence shows that ivabradine does not seem to affect the risks of all-cause mortality and cardiovascular mortality. The effects on quality of life were small and possibly without relevance to patients on the KCCQ and were very uncertain for the MLWHFQ. The effects on serious adverse events, myocardial infarction and hospitalisation are uncertain. Ivabradine seems to increase the risk of atrial fibrillation, bradycardia and non-serious adverse events.PROSPERO registration number: CRD42018112082.